ABVC Biopharma Files 8-K: Regulation FD & Exhibits
Ticker: ABVC · Form: 8-K · Filed: Aug 20, 2024 · CIK: 1173313
| Field | Detail |
|---|---|
| Company | Abvc Biopharma, Inc. (ABVC) |
| Form Type | 8-K |
| Filed Date | Aug 20, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
ABVC filed an 8-K for standard disclosures and exhibits. Nothing major new.
AI Summary
On August 20, 2024, ABVC Biopharma, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific new material events, significant financial figures, or forward-looking statements were detailed in the provided excerpt.
Why It Matters
This filing indicates routine corporate reporting, including disclosures and financial exhibits, which are standard for public companies to maintain transparency with investors.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any new significant risks or material adverse events.
Key Players & Entities
- ABVC BIOPHARMA, INC. (company) — Registrant
- August 20, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 44370 Old Warm Springs Blvd. Fremont, CA 94538 (address) — Principal executive address
FAQ
What is the primary purpose of this 8-K filing for ABVC Biopharma, Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on August 20, 2024.
In which U.S. state is ABVC Biopharma, Inc. incorporated?
ABVC Biopharma, Inc. is incorporated in Nevada.
What is the principal executive address of ABVC Biopharma, Inc.?
The principal executive address of ABVC Biopharma, Inc. is 44370 Old Warm Springs Blvd., Fremont, CA 94538.
Does this filing indicate any specific new business developments or material changes for ABVC Biopharma, Inc.?
Based on the provided excerpt, the filing primarily concerns routine disclosures and exhibits, and does not detail any specific new business developments or material changes.
Filing Stats: 573 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-08-20 16:30:19
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ABVC The Nasdaq Stock Mar
Filing Documents
- ea0211916-8k_abvc.htm (8-K) — 26KB
- ea021191601ex99-1_abvc.htm (EX-99.1) — 44KB
- ex99-1_001.jpg (GRAPHIC) — 131KB
- ex99-1_002.jpg (GRAPHIC) — 555KB
- ex99-1_003.jpg (GRAPHIC) — 234KB
- ex99-1_004.jpg (GRAPHIC) — 338KB
- ex99-1_005.jpg (GRAPHIC) — 278KB
- ex99-1_006.jpg (GRAPHIC) — 225KB
- ex99-1_007.jpg (GRAPHIC) — 248KB
- ex99-1_008.jpg (GRAPHIC) — 294KB
- ex99-1_009.jpg (GRAPHIC) — 216KB
- ex99-1_010.jpg (GRAPHIC) — 256KB
- ex99-1_011.jpg (GRAPHIC) — 308KB
- ex99-1_012.jpg (GRAPHIC) — 283KB
- ex99-1_013.jpg (GRAPHIC) — 303KB
- ex99-1_014.jpg (GRAPHIC) — 231KB
- ex99-1_015.jpg (GRAPHIC) — 303KB
- ex99-1_016.jpg (GRAPHIC) — 307KB
- ex99-1_017.jpg (GRAPHIC) — 231KB
- ex99-1_018.jpg (GRAPHIC) — 342KB
- ex99-1_019.jpg (GRAPHIC) — 380KB
- ex99-1_020.jpg (GRAPHIC) — 313KB
- ex99-1_021.jpg (GRAPHIC) — 245KB
- ex99-1_022.jpg (GRAPHIC) — 219KB
- ex99-1_023.jpg (GRAPHIC) — 232KB
- ex99-1_024.jpg (GRAPHIC) — 146KB
- 0001213900-24-071145.txt ( ) — 8884KB
- abvc-20240820.xsd (EX-101.SCH) — 3KB
- abvc-20240820_lab.xml (EX-101.LAB) — 33KB
- abvc-20240820_pre.xml (EX-101.PRE) — 22KB
- ea0211916-8k_abvc_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 20, 2024, ABVC BioPharma, Inc. (the "Company") updated its corporate presentation . A copy of the Company's presentation is attached as Exhibit 99.1 and incorporated herein by reference. Neither this Current Report on Form 8-K, nor any exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the Securities described herein. Such disclosure does not constitute an offer to sell, or the solicitation of an offer to buy nor shall there be any sales of the Company's securities in any state in which such offer, solicitation or sale would be unlawful. The information in Item 7.01 of this Current Report on Form 8-K (including Exhibits 99.1 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit 99.1 Power Point Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABVC BioPharma, Inc. August 20, 2024 By: /s/ Uttam Patil Uttam Patil Chief Executive Officer 2